AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01321944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Smoker Outreach Program
Description: Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs.
Study NCT02964559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01791049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1607
Study NCT01791049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03939767 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
Study NCT03453619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: APL-2 administered as a daily subcutaneous infusion for 48 weeks
Study NCT04517695 — intervention group
Intervention type: DEVICE
Intervention: BVA-100
Description: The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
Study NCT04517695 — intervention group
Intervention type: DEVICE
Intervention: Transpulmonary Thermodilution (TPTD)
Description: TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
Study NCT04517695 — intervention group
Intervention type: DEVICE
Intervention: Sublingual Microcirculation
Description: With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
Study NCT02290691 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: Influenza Vaccine
Study NCT02290691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Influenza Vaccine
Study NCT03695614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
Study NCT00336284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Monitoring
Description: Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
Study NCT00336284 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In-Office Conventional Follow-up
Description: Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
Study NCT02321787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound for confirmation of successful caudal block
Description: Use of ultrasound for confirmation of successful caudal block
Study NCT02810912 — intervention group
Intervention type: OTHER
Intervention: the effect of surgical position
Description: Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
Study NCT02407080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7388
Description: RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
Study NCT02407080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
Study NCT03539744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: capsule, oral
Study NCT03539744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral, locally available form
Study NCT03539744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral, locally available form
Study NCT03539744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet; oral
Study NCT03978052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG
Description: FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight >50kg: 5 capsules/day.
Study NCT03978052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EGCG
Description: Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight >50kg: 5 capsules/day.
Study NCT03978052 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Healthy lifestyle recommendations
Description: Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.
Study NCT03978052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention
Description: * Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions.
Study NCT03978052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal lifestyle intervention
Description: * Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions.
Study NCT03017872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.
Study NCT03017872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRTIs
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.
Study NCT03017872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg tablet by mouth once daily for 96 weeks.
Study NCT03017872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800mg tablet by mouth once daily for 96 weeks.
Study NCT03017872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: 800mg tablet by mouth once daily for 96 weeks.
Study NCT03017872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.
Study NCT03017872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100mg tablet by mouth once daily for 96 weeks.
Study NCT01299337 — intervention group
Intervention type: DRUG
Intervention: T3
Description: Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
Study NCT01337843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness Workbook
Description: A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
Study NCT01337843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Management Print Materials
Description: Print materials comparable to the content within Wellness Workbook
Study NCT01814319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid 1 gr oral twice daily
Description: Probenecid 1 gram oral twice daily
Study NCT01814319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral twice daily
Study NCT01139411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Control with Enhanced Parent Involvement
Study NCT01139411 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Weight Control with Minimal Parent Involvement
Study NCT03724383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Factor Management Consult
Description: Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
Study NCT03724383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Classes
Description: Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
Study NCT03724383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Classes
Description: Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
Study NCT03724383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Classes
Description: Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
Study NCT03724383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise program
Description: The interval and resistance training program will mirror the supervised exercise.
Study NCT01236066 — intervention group
Intervention type: OTHER
Intervention: Database analysis
Description: Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
Study NCT01618045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fermented Papaya Preparation (FPP)
Description: Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
Study NCT04860557 — intervention group
Intervention type: OTHER
Intervention: cognitive skill, dual task and physical activity assessment
Description: Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
Study NCT00491036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraaortic balloon pump
Description: intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
Study NCT03892668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
Study NCT03892668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
Study NCT03892668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
Study NCT02890303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zepto System
Description: Anterior Capsulotomy using the Zepto System.
Study NCT02350166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: laparoscopic-assisted small-incision surgery
Study NCT04689490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Only diagnostic tests
Study NCT00388388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan, hydrochlorothiazide
Description: Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Study NCT00388388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan, hydrochlorothiazide
Description: Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Study NCT00925106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex capsule
Description: Single dose 200 mg commercial Celebrex capsule
Study NCT02186834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
Study NCT03462082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetric STN-DBS
Description: Asymmetric deep brain stimulation
Study NCT00925106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation D1
Description: Single dose 150 mg celecoxib as formulation D1
Study NCT00023920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT00023920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC
Study NCT00925106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation D2
Description: Single dose 150 mg celecoxib as formulation D2
Study NCT00925106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation D3
Description: Single dose 150 mg celecoxib as formulation D3
Study NCT02136758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC lifestyle modification program
Description: Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
Study NCT01110330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Study NCT01110330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream (formulation F012) (Nizoral)
Description: A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Study NCT01110330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream (formulation F126)
Description: A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Study NCT03391024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBL Experimental Navigation System
Description: Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
Study NCT03853538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one hemiface.
Study NCT04749758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF treatment
Description: SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
Study NCT02687685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin contact immediate
Description: Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
Study NCT02687685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skin to skin contact early
Description: Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
Study NCT05878327 — intervention group
Intervention type: OTHER
Intervention: Thrombophilia screening
Description: No intervention. Blood is drawn for analysis.
Study NCT04683549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy
Description: Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy.